MetLife, Inc. filings document the regulatory record of a Delaware financial services company with NYSE-listed common stock and preferred securities, including depositary shares tied to Series E and Series F preferred stock. Recent Form 8-K reports furnish earnings releases, quarterly financial supplements, total assets under management fact sheets and Regulation FD disclosures related to variable investment income.
The filings also cover capital-structure actions such as subordinated debenture issuance and preferred stock dividend declarations. Proxy materials describe board composition, committee assignments, executive compensation and shareholder voting matters, while material-event reports record governance changes and other corporate disclosures.
MetLife Inc — The Vanguard Group filed Amendment No. 11 to its Schedule 13G/A reporting 0 shares and 0% beneficial ownership of MetLife common stock as of the amendment. The filing explains an internal realignment on January 12, 2026 that disaggregated certain subsidiaries' holdings from The Vanguard Group, Inc.
The report lists zero voting and dispositive power (sole and shared) for the filer and is signed by Ashley Grim on 03/27/2026.
MetLife reported insider sales of Common Stock. The excerpt lists dispositions of 562 shares on 01/09/2026 and 725 shares on 03/02/2026. The transactions are reported on a Form 144 covering Common Stock and reference NYSE trading.
MET filed a Rule 144 notice reporting sales of Common Stock.
The notice lists prior purchases and recent dispositions of Common Stock, including a 100-share purchase noted with 05/29/2015 (broker: GOLDMAN SACHS) and sales of 562 shares on 01/09/2026 and 725 shares on 03/02/2026. The filing identifies the NYSE and an entry date of 03/20/2026.
MetLife (MET) reported Form 144 notices for sales of Common Stock. The excerpt lists individual dispositions dated 01/09/2026 (562 shares) and 03/02/2026 (725 shares). The filings identify brokers and plan/ account names associated with the transactions.
MetLife reported proposed sales of Common Stock under Form 144. The filing lists a sale of 562 shares on 01/09/2026 with a value of $44,628.42 and a sale of 725 shares on 03/02/2026 with a value of $53,099. The securities are Common Stock traded on the NYSE; a broker address for Barclays is shown.
MetLife Inc. director Daniel S. Glaser reported an acquisition of 273 shares of common stock as a grant under non-management director compensation arrangements. The grant was valued at $75.34 per share, and he elected to defer receipt of these shares into the MetLife Deferred Compensation Plan for Non-Management Directors.
Following this award, Glaser directly holds 1,380 common shares. The filing also notes 198 common shares held indirectly in a Grantor Retained Annuity Trust, which were previously reported as directly owned due to an administrative error and are now correctly classified as indirectly held.
MetLife Inc. director Daniel S. Glaser updated his initial ownership report for the company’s common stock. The amended Form 3 shows he holds 1,107 shares directly and 198 shares indirectly through a Grantor Retained Annuity Trust (GRAT).
The footnote explains the GRAT-held shares were previously reported as directly owned due to an administrative error, and this amendment corrects the ownership classification without indicating any new purchase or sale of shares.
MetLife director Diana McKenzie reported a small compensation-related share increase. She acquired 189 shares of MetLife common stock on an imputed basis at $70.60 per share through reinvested dividends in the MetLife Deferred Compensation Plan for Non-Management Directors. Following this grant, she directly holds 23,751 common shares, reflecting routine deferred compensation rather than an open-market purchase.
MetLife Inc. director Jeh C. Johnson reported an acquisition of 65 shares of MetLife common stock on March 10, 2026 at an imputed price of $70.60 per share. The filing states this resulted from imputed reinvestment of dividends on deferred shares under MetLife’s Deferred Compensation Plan for Non-Management Directors.
After this award, Johnson directly holds 8,129 MetLife common shares. The footnote explains that the deferred shares represent MetLife common stock that has become payable, but whose receipt Johnson has chosen to defer.
MetLife director Robert Glenn Hubbard received 771 shares of Common Stock at $70.60 per share as a grant under the MetLife Deferred Compensation Plan for Non-Management Directors.
The footnote explains this was an imputed reinvestment of dividends on deferred shares. After this compensation-related acquisition, he directly holds 104,630 MetLife shares.